| Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia P Blombery, MA Anderson, J Gong, R Thijssen, RW Birkinshaw, ... Cancer discovery 9 (3), 342-353, 2019 | 379 | 2019 |
| Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax MA Anderson, C Tam, TE Lew, S Juneja, M Juneja, D Westerman, M Wall, ... Blood, The Journal of the American Society of Hematology 129 (25), 3362-3370, 2017 | 204 | 2017 |
| BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax VS Lin, TE Lew, SM Handunnetti, P Blombery, T Nguyen, DA Westerman, ... Blood, The Journal of the American Society of Hematology 135 (25), 2266-2270, 2020 | 87 | 2020 |
| Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition TE Lew, VS Lin, ER Cliff, P Blombery, ER Thompson, SM Handunnetti, ... Blood Advances 5 (20), 4054-4058, 2021 | 48 | 2021 |
| Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance P Blombery, ER Thompson, TE Lew, IS Tiong, R Bennett, CY Cheah, ... Blood advances 6 (20), 5589-5592, 2022 | 43 | 2022 |
| Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL P Blombery, TE Lew, MA Dengler, ER Thompson, VS Lin, X Chen, ... Blood, The Journal of the American Society of Hematology 139 (8), 1198-1207, 2022 | 43 | 2022 |
| Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months TE Lew, MA Anderson, VS Lin, SM Handunnetti, NA Came, P Blombery, ... Blood advances 4 (1), 165-173, 2020 | 40 | 2020 |
| Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy R Thijssen, L Tian, MA Anderson, C Flensburg, A Jarratt, AL Garnham, ... Blood, The Journal of the American Society of Hematology 140 (20), 2127-2141, 2022 | 35 | 2022 |
| Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency CY Cheah, TE Lew, JF Seymour, K Burbury Acta haematologica 130 (4), 254-259, 2013 | 35 | 2013 |
| Early serum creatinine accurately predicts acute kidney injury post cardiac surgery K Grynberg, KR Polkinghorne, S Ford, F Stenning, TE Lew, JA Barrett, ... BMC nephrology 18, 1-7, 2017 | 30 | 2017 |
| Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination TE Lew, JF Seymour Journal of Hematology & Oncology 15 (1), 75, 2022 | 25 | 2022 |
| Evaluation of pharmacist‐led physician‐supported inpatient deprescribing model in older patients admitted to an acute general medical unit EL Potter, TE Lew, M Sooriyakumaran, AM Edwards, E Tong, AK Aung Australasian journal on ageing 38 (3), 206-210, 2019 | 18 | 2019 |
| How I treat chronic lymphocytic leukemia after venetoclax TE Lew, CS Tam, JF Seymour Blood, The Journal of the American Society of Hematology 138 (5), 361-369, 2021 | 17 | 2021 |
| Rehabilitation in patients with lymphoma: an overview of Systematic Reviews B Amatya, F Khan, TE Lew, M Dickinson Journal of rehabilitation medicine, 2021 | 16 | 2021 |
| Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discov 9, 342–353 … P Blombery, MA Anderson, JN Gong, R Thijssen, RW Birkinshaw, ... CD 18, 1119, 2019 | 12 | 2019 |
| Treatment approaches for patients with TP53-mutated mantle cell lymphoma TE Lew, A Minson, M Dickinson, SM Handunnetti, P Blombery, A Khot, ... The Lancet Haematology 10 (2), e142-e154, 2023 | 11 | 2023 |
| A case of multi-drug resistant ESBL-producing Shigella sonnei acute acalculous cholecystitis and gastroenteritis in a returned traveller E Williams, TE Lew, A Fuller, DW Spelman, AW Jenney Journal of Travel Medicine 25 (1), tay029, 2018 | 10 | 2018 |
| Promises and pitfalls of targeted agents in chronic lymphocytic leukemia TE Lew, MA Anderson, JF Seymour Cancer Drug Resistance, 2020 | 9 | 2020 |
| T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease TE Lew, ERS Cliff, M Dickinson, CS Tam, JF Seymour, P Blombery, ... Bone Marrow Transplantation 56 (11), 2857-2859, 2021 | 7 | 2021 |
| Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy TE Lew, CY Cheah, DA Carney, HM Prince, M Wolf, A Bazargan, ... Leukemia & Lymphoma 57 (5), 1044-1053, 2016 | 5 | 2016 |
John F SeymourProfessor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal MelbourneVerified email at petermac.org
